Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Acquired by Tamar Securities LLC

Tamar Securities LLC boosted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 4.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,766 shares of the biopharmaceutical company’s stock after purchasing an additional 486 shares during the period. Regeneron Pharmaceuticals comprises approximately 2.8% of Tamar Securities LLC’s holdings, making the stock its 12th largest position. Tamar Securities LLC’s holdings in Regeneron Pharmaceuticals were worth $8,794,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. TrueWealth Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $207,000. Walker Asset Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $436,000. Ascent Group LLC boosted its stake in shares of Regeneron Pharmaceuticals by 55.1% during the 2nd quarter. Ascent Group LLC now owns 940 shares of the biopharmaceutical company’s stock valued at $547,000 after buying an additional 334 shares during the last quarter. Wipfli Financial Advisors LLC bought a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at $555,000. Finally, US Bancorp DE grew its stake in Regeneron Pharmaceuticals by 1.3% in the third quarter. US Bancorp DE now owns 5,783 shares of the biopharmaceutical company’s stock worth $3,984,000 after purchasing an additional 74 shares in the last quarter. 84.25% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Up 1.3 %

Regeneron Pharmaceuticals stock traded up $9.67 during trading on Wednesday, hitting $737.14. 107,498 shares of the company were exchanged, compared to its average volume of 616,375. Regeneron Pharmaceuticals, Inc. has a 52 week low of $538.01 and a 52 week high of $779.00. The business’s 50 day moving average is $732.22 and its 200 day moving average is $690.27. The company has a market capitalization of $80.28 billion, a P/E ratio of 15.34, a PEG ratio of 2.17 and a beta of 0.22. The company has a current ratio of 5.36, a quick ratio of 4.52 and a debt-to-equity ratio of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last issued its quarterly earnings results on Thursday, November 3rd. The biopharmaceutical company reported $9.98 EPS for the quarter, topping analysts’ consensus estimates of $8.55 by $1.43. The business had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.79 billion. Regeneron Pharmaceuticals had a return on equity of 31.16% and a net margin of 39.17%. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.45 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on REGN shares. EF Hutton Acquisition Co. I reissued a “buy” rating and issued a $851.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, January 11th. JPMorgan Chase & Co. raised Regeneron Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $850.00 target price on the stock in a report on Friday, January 20th. SVB Leerink upped their price target on Regeneron Pharmaceuticals from $756.00 to $770.00 and gave the company a “market perform” rating in a report on Friday, November 4th. Cowen raised their price objective on shares of Regeneron Pharmaceuticals from $655.00 to $750.00 and gave the stock a “market perform” rating in a research note on Thursday, October 20th. Finally, Guggenheim dropped their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $915.00 and set a “buy” rating on the stock in a research note on Friday, November 11th. One analyst has rated the stock with a sell rating, six have issued a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $786.15.

Insider Activity

In related news, EVP Plew Daniel P. Van sold 11,972 shares of the stock in a transaction dated Wednesday, November 23rd. The stock was sold at an average price of $740.75, for a total transaction of $8,868,259.00. Following the completion of the sale, the executive vice president now directly owns 30,578 shares in the company, valued at approximately $22,650,653.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director N Anthony Coles sold 5,758 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, December 28th. The shares were sold at an average price of $714.11, for a total transaction of $4,111,845.38. Following the transaction, the director now owns 1,093 shares in the company, valued at approximately $780,522.23. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Plew Daniel P. Van sold 11,972 shares of the firm’s stock in a transaction that occurred on Wednesday, November 23rd. The stock was sold at an average price of $740.75, for a total transaction of $8,868,259.00. Following the sale, the executive vice president now owns 30,578 shares in the company, valued at approximately $22,650,653.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,212 shares of company stock worth $14,070,511. 8.99% of the stock is owned by company insiders.

About Regeneron Pharmaceuticals

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.